Express Mail No.: EL 477 033 69

FORM PTO-1390 (REV. 11-94) U S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER



TRANSMIT FAL LETTER TO THE UNITED STATES DESIGNARED/ELECTED OFFICE (DO/EO/US)

TRA

2988-0695

10/031113

INTERNATIONAL APPLICATION NO
PCT/FR00/01579

INTERNATIONAL FILING DATE June 8, 2000

PRIORITY DATE CLAIMED July 16, 1999

TITLE OF INVENTION

AMINOGUANIDINE BICARBONATE WITH PARTICULAR PROPERTIES AND PROCESS FOR MANUFACTURING IT

APPLICANT(S) FOR DO/EO/US

Jean-Michel Bossoutrot and Paul Bourdauducq

Applicant herewith submits to the United States Designated/ Elected Office (DO/EO/US) the following items under 35 U.S.C. 371:

- 1.

 ☑ This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
- 2.

 This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
- 3. This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
- 4.

 A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
- - a. \Box is transmitted herewith (required only if not transmitted by the international Bureau).
 - b.

 has been transmitted by the International Bureau.
 - c. \square is not required, as the application was filed in the United States Receiving Office (RO/US)
 - A translation of the International Application into English (35 U.S.C. 371(c)(2)).
 - □ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. \Box are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. \square have been transmitted by the International Bureaus.
 - c. \square have not been made; however, the time limit for making such amendments has NOT expired.
 - d. D have not been made and will not be made.
 - □ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 37(c)(3)).
 - ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
 - □ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Figure 11. to 16. below concern document(s) or information included:

- An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
- 12.

 An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
- - □ A SECOND or SUBSEQUENT preliminary amendment.
- 14.

 A substitute specification.

- 15.

 A change of power of attorney and/or address letter.
- 16.

 ✓ Other items or information:

International Publication WO 01/05752 A1
International Preliminary Examination Report (PCT/IPEA/409)
PCT/IB/306

IC12 Rec'd PCT/PTO INTERNATIONAL FILING DATE INTERNATIONAL APPLICATION NO June 8, 2000 PCT/FR00/01579 ☑ The U.S. National Fee (35 U.S.C. 371(c)(1)) and other fees as follows: 17. **CLAIMS** (3)NUMBER (2)NUMBER (5)CALCULATIONS (4)RATE (1)FOR **FILED EXTRA TOTAL** \$ 0.00 0 X \$18.00 -20 13 **CLAIMS** INDEPENDENT X \$84.00 0.00 0 3 -3 **CLAIMS** + \$280.00MULTIPLE DEPENDENT CLAIM(S) (if applicable) BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)): CHECK ONE BOX ONLY □ International preliminary examination fee paid to USPTO (37 CFR 1.482) □ No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) □ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1,040.00 □ International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2) to (4) \$100.00 \$ 890.00 ☑ Filing with EPO or JPO search report\$890.00 Surcharge of \$130.00 for furnishing the National fee or oath or declaration later than 20 30 mos. from the earliest claimed priority date (37 CFR 1.492(e)). TOTAL OF ABOVE CALCULATIONS 890.00 Reduction by 1/2 for filing by small entity, if applicable. Affidavit must be \$ 0.00 filed also. (Note 37 CFR 1.9, 1.27, 1.28). **SUBTOTAL** 890.00 Processing fee of \$130.00 for furnishing the English Translation later than 20 30 mos. from the earliest claimed priority date (37 CFR 1.492(f)). 890.00 TOTAL FEES ENCLOSED A check in the amount of \$_ to cover the above fees is enclosed. a. Please charge Deposit Account No. 16-1150 in the amount of \$890.00 to cover the above fees. A copy of b. \boxtimes this sheet is enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any c. overpayment to Deposit Account No. 16-1150. A copy of this sheet is enclosed. 18. Other instructions
 ■ Please calculate the fee after entering the Preliminary Amendment.

PENNIE & EDMONDS LLP 1155 Avenue of Americas New York, N.Y. 10036-2711

Charles E. Miller		24,576	January 11, 2002
NAME	SIGNATURE	REGISTRATION NUMBER	DATE



EXPRESS MAIL NO.: EL 477 033 690 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Bossoutrot et al.

Group Art Unit: To be assigned

Serial No.: to be assigned

Examiner: To be assigned

Filed: Concurrently filed

Attorney Docket No.: 2988-695

For:

AMINOGUANIDINE BICARBONATE

New York, NY

WITH PARTICULAR PROPERTIES

January 11, 2001

AND PROCESS FOR MANUFACTURING IT

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Applicant respectfully requests entry of the following amendment and remarks in to the file of the above identified application.

IN THE CLAIMS:

Please cancel claims 1-9.

Please add the following new claims:

A process for manufacturing aminoguanidine bicarbonate, 10. (New) comprising combining an aqueous solution of cyanamide and an aqueous solution of hydrazine hydrate to form a reaction medium in the presence of CO2, wherein the molar ratio of the cyanamide to the hydrazine used in the process is smaller than 1.

- 11. (New) The process as claimed in claim 10, wherein the cyanamide/hydrazine molar ratio used is between about 0.8 and about 0.99.
- 12. (New) The process as claimed in claim 11, wherein the cyanamide/hydrazine molar ratio is between about 0.85 to about 0.95.
- 13. (New) The process as claimed in claim 10, wherein the pH of the reaction medium is between about 6.5 and about 8.
- 14. (New) The process as claimed in claim 13, wherein the pH of the reaction medium is between about 7 and about 7.3.
- 15. (New) The process as claimed in claim 10, wherein the temperature of the reaction medium is between about 35°C and about 70°C.
- 16. (New) The process as claimed in claim 15, wherein the temperature of the reaction medium is between about 40°C and about 50°C.
- 17. (New) The process as claimed in claim 10, wherein the pH of the hydrazine hydrate solution is adjusted using CO₂, and the aqueous cyanamide solution is then introduced.
- 18. (New) The process as claimed in claim 10, wherein the hydrazine hydrate solution and CO₂ are simultaneously added to the cyanamide solution.

- 19. (New) The process as claimed in claim 10, wherein the cyanamide solution or of the hydrazine hydrate solution is kept being added to the reaction medium for between about 1 and about 3 hours.
- 20. (New) A process for manufacturing aminoguanidine bicarbonate, comprising combining an aqueous solution of cyanamide and an aqueous solution of hydrazine hydrate to form a reaction medium in the presence of CO_2 , wherein the molar ratio of the cyanamide to the hydrazine used in the process is between about 0.8 and about 0.99, wherein the pH of the reaction medium is between about 6.5 and about 8, and wherein the temperature of the reaction medium is between about 35°C and about 70°C.
- 21. (New) A virtually spherical aggregate of amino guanidine bicarbonate crystals with a mean diameter of between about 80 and about 500 μm .
- 22. (New) The virtually spherical aggregate of amino guanidine bicarbonate crystals of claim 21, wherein the mean diameter is between about 100 and about 250 μ m.

REMARKS

Claim 1-9 has been canceled. Claims 10-22 have been added.

Support for the new claims can be found in the original specification, e.g., original claims. None of the amendment has narrowed scope of claims. No new matter is believed to be introduced.

No fee, other than that for the application filing fee, is believed due for the filing of this response. Should any fees be required, however, please charge such fees to Pennie & Edmonds LLP Deposit Account No. 16-1150.

Respectfully submitted,

Date: January 11, 2002

Charles E. Miller (Reg. No.)

PENNIE & EDMONDS LLP 1155 Avenue of the Americas New York, New York 10036-2711 (212) 790-9090

Attorneys For Applicant

WO 01/05752

-

PCT/FR00/01579

AMINOGUANIDINE BICARBONATE WITH PARTICULAR PROPERTIES AND PROCESS FOR MANUFACTURING IT

The present invention relates to a process

for manufacturing aminoguanidine bicarbonate. The

invention also relates to an aminoguanidine bicarbonate

with particular properties.

The manufacture of aminoguanidine bicarbonate (AGB) by reacting an aqueous solution of cyanamide with hydrazine followed by an addition of CO₂ is known. Since the placing in contact of cyanamide with hydrazine in alkaline medium also leads to the dimerization of the cyanamide, it is necessary to use a large excess of cyanamide to achieve a suitable yield of aminoguanidine bicarbonate.

Thus, patent DD 689 191 teaches working with a 100% excess of cyanamide (i.e. cyanamide/hydrazine molar ratio = 2/1) to obtain a yield (relative to the hydrazine used) of 80% of AGB, after reaction for 60 hours. An AGB yield of about 90% may be achieved after reaction for 27 hours when concentrated solutions of cyanamide and hydrazine are used with a 100% excess of cyanamide (DD 730 331).

Since cyanamide is a very expensive product,

25 attempts to reduce this excess have been the subject of
much research.

Specifically, patent SU 981 314 discloses a cyanamide/hydrazine molar ratio of between 1.25 and 1.8. It is mentioned that an AGB yield (relative to the hydrazine) of 95% is obtained with a

5 cyanamide/hydrazine molar ratio of 1.8. It also teaches that the yields fall to 90% and 85% for molar ratios of 1.5 and 1.25, respectively.

The same trend has been observed by other authors. Thus, a fall of about 12 points in the yield was recorded when the cyanamide/hydrazine molar ratio went from 1.2 to 1 (DD 249 009).

The combined literature in this field encourages a person skilled in the art to work with an excess of cyanamide to obtain a yield of aminoguanidine bicarbonate.

The Applicant Company has developed a process for manufacturing aminoguanidine bicarbonate from cyanamide and hydrazine and has observed, surprisingly, by working with a slight deficit of cyanamide relative to the stoichiometric amount, yields of AGB that are as high as, or even higher than, those achieved with processes using a large excess of cyanamide.

According to the present invention, the process consists in reacting an aqueous solution of cyanamide with an aqueous solution of hydrazine hydrate in the presence of CO₂, characterized in that the

process is performed with a slight deficit of cyanamide relative to the stoichiometry.

The cyanamide/hydrazine molar ratio used is preferably between 0.80 and 0.99 and advantageously between 0.85 and 0.95.

The pH of the reaction medium is generally between 6.5 and 8, preferably between 7 and 7.3. The pH may be adjusted by any suitable means and especially using CO_2 .

The concentration of the aqueous solutions may vary within a wide range. It is usually preferred to use an aqueous cyanamide solution with a concentration of between 15% and 50% by weight. The hydrazine concentration in the aqueous solution is advantageously between 15% and 64% by weight.

The temperature of the reaction medium is generally between 35°C and 70°C. A temperature of between 40°C and 50°C gives an aminoguanidine bicarbonate whose structure and specific properties are commercially very advantageous.

One embodiment consists in adjusting, using CO_2 (carbon dioxide), the pH of the hydrazine hydrate solution to the desired value and then in introducing an aqueous solution of cyanamide once the temperature of the hydrazine solution has been raised to about a few degrees below the temperature chosen for the reaction.

The pH of the reaction medium is maintained using CO_2 at the desired value during the introduction, or addition, of the cyanamide solution and throughout the reaction.

- Another embodiment consists in simultaneously adding an aqueous hydrazine hydrate solution and carbon dioxide to an aqueous cyanamide solution initially maintained a few degrees below the temperature chosen for the reaction.
- 10 Irrespective of the embodiment, the total reaction time is generally between 6 and 15 hours and preferably between 7 and 10 hours. The duration of the addition of cyanamide or of hydrazine hydrate is generally between 1 and 3 hours and preferably in the 15 region of 2 hours.

After the reaction, the reaction medium is cooled to room temperature and the aminoguanidine bicarbonate thus obtained is spin-filtered or filtered and optionally dried.

With the process according to the invention, yields of greater than 90% and preferably greater than 95% are obtained with a purity of greater than 99%, or even greater than 99.5%.

A subject of the present invention is also an aminoguanidine bicarbonate with a particular structure and particular specific properties. It is characterized by a virtually spherical crystal aggregate with a mean

25

diameter of between 80 and 500 μm . The aggregate preferably has a mean diameter of between 100 and 250 μm , the mean diameter being determined by laser granulometry.

The aminoguanidine bicarbonate according to the invention also has the advantage of being easy to separate out from the reaction medium by any known means, for example by filtering or spin-filtering and drying, thus being distinguished from platelet crystals.

EXPERIMENTAL SECTION

Example 1

110.9 g of hydrazine hydrate with a purity of 99.2% (2.2 mol) and 300 g of demineralized water are placed in a one liter reactor at room temperature. The pH of the aqueous solution is in the region of 11. Carbon dioxide is then bubbled into the aqueous solution for about 1 hour, which represents 58 g or 1.3 mol of CO₂, until a pH in the region of 7 is obtained, while maintaining the temperature of the solution at about 40°C.

171.4 g of an aqueous 49% cyanamide solution (2 mol) are then added over about 2 hours, while continuing the addition of CO_2 so as to maintain the pH of the reaction medium in the region of 7. During the addition, the temperature of the medium is raised to $45^{\circ}C$ and the medium is maintained at this temperature

for 8 hours with adjustment of the pH to a value in the region of 7 by small additions of CO_2 .

The total amount of CO_2 added is 104 g, i.e. 2.36 mol.

- At the end of the reaction, the reaction medium is allowed to cool to room temperature and the AGB crystals are then filtered off and washed with 250 ml of water and finally dried under vacuum at a temperature of between 35°C and 40°C.
- After drying, 260 g of crystals with a purity of 99.7%, determined by assaying with perchloric acid, are obtained. The crude yield relative to the cyanamide is 95.6%.

The crystals obtained are in the form of virtually spherical aggregates (photograph No. 1 by scanning electron microscopy).

Example 2

The process is performed as described in Example 1, except that the aqueous hydrazine hydrate solution is maintained at 55°C instead of 40°C and that, during the addition of the cyanamide, the reaction medium is brought to 65°C and is maintained at this temperature for 4 hours.

After drying, 261.1 g of crystals in the form 25 of platelets (photograph No. 2) are obtained in a purity of 99.6%. The crude yield relative to the cyanamide is 96%.

Example 3

Example 1 is extrapolated to the industrial scale, using a 15 \mbox{m}^3 reactor.

After spin-filtering for 20 minutes, the aggregates contain a moisture content of only 7%. At the end of the spin-filtering, the aggregates are virtually spherical of the type in Example 1, with a narrow particle size distribution free of fine particles, of less than 40 µm in diameter.

10 Example 4

Example 2 is repeated on the industrial scale, using a $15~\text{m}^3$ reactor.

After spin-filtering for 3 hours, the platelets contain a moisture content of 20% and, at the end of the spin-filtering, the platelets have a mean diameter of 70 μ m with a very broad particle size distribution with 20% of the population of particles having a diameter of less than 20 μ m.

Example 5

- The procedure described in Example 1 is repeated, except that the duration of addition of the cyanamide is 5 hours instead of 2 hours and the duration of the reaction after the addition is reduced from 8 to 5 hours.
- 25 The yield and also the purity of the AGB crystals obtained are similar to those of Example 1.

 However, the crystals are rather in the form of

platelets (photograph No. 3) and the spin-filtering time is longer.

Example 6

- 171.4 g of an aqueous 49% cyanamide solution
 5 (2 mol) and 300 g of water are placed in a one liter
 reactor at room temperature. The pH of the resulting
 solution is in the region of 5. The solution is then
 brought to 40°C, after which 110.9 g of 99.2% hydrazine
 hydrate (2.2 mol) and 75 g (1.7 mol) of CO₂, to maintain
 10 the pH at about 7, are simultaneously added over 2
 hours. The reaction medium is then maintained at 45°C
 for 8 hours with a small addition of CO₂ to adjust the
 pH to about 7. The total amount of CO₂ added is 94.5 g
 (2.15 mol).
- The reaction medium is then allowed to cool to room temperature and the AGB is filtered off and washed with 250 ml of water. Finally, it is dried under vacuum at a temperature of between 35°C and 40°C.

After drying, 259 g of AGB aggregates similar 20 to those of Example 1, with a purity of 99.6%, are obtained.

The crude yield of aminoguanidine bicarbonate is 95.2% relative to the cyanamide.

CLAIMS

- 1. A process for manufacturing
- 5 aminoguanidine bicarbonate from an aqueous solution of cyanamide and an aqueous solution of hydrazine hydrate in the presence of CO₂, characterized in that the process is performed with a slight deficit of cyanamide relative to the stoichiometry.
- 10 2. The process as claimed in claim 1, characterized in that the cyanamide/hydrazine molar ratio used is between 0.8 and 0.99.
- 3. The process as claimed in claim 2, characterized in that the cyanamide/hydrazine molar ratio is between 0.85 and 0.95.
 - 4. The process as claimed in one of claims 1 to 3, characterized in that the pH of the reaction medium is between 6.5 and 8 and preferably between 7 and 7.3.
- 5. The process as claimed in one of claims 1 to 4, characterized in that the temperature of the reaction medium is between 35°C and 70°C and preferably between 40°C and 50°C.
- 6. The process as claimed in one of claims
 1 to 5, characterized in that the pH of the hydrazine
 hydrate solution is adjusted using CO₂, and the aqueous
 cyanamide solution is then introduced.

- 7. The process as claimed in one of claims 1 to 5, characterized in that an aqueous hydrazine hydrate solution and carbon dioxide are simultaneously added to an aqueous cyanamide solution.
- 5 8. The process as claimed in either of claims 6 and 7, characterized in that the duration of the addition of cyanamide or of hydrazine hydrate is between 1 and 3 hours.
- 9. A virtually spherical aggregate of amino guanidine bicarbonate crystals with a mean diameter of between 80 and 500 μm and preferably between 100 and 250 μm .

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

WIPO

International Bureau

(43) International publication date 25 January 2001 (25.01.2001)

PCT

(10) International publication number

WO 01/05752 A1

(51) International patent classification⁷:

C07C 277/02, 279/02

(21) International application number:

PCT/FR00/01579

(22) International filing date:

8 June 2000 (08.06.2000)

(25) Language of filing:

French

(26) Language of publication:

French

FR

(30) Data relating to the priority: 99/09,257 16 July 1999 (16.07.1999)

ATOFINA [FR/FR]; 4/8, cours Michelet, F-92800
Puteaux (FR)

(72) Inventors; and

The little was the first

(75) Inventors/Applicants (US only): BOSSOUTROT, Jean-Michel [FR/FR]; 11, avenue de Gadagne, F-69230 Saint-Genis Laval (FR). BOURDAUDUCQ, Paul [FR/FR]; 8, rue des Anémones, F-69630 Chaponost (FR).

- (74) Representative: DANG, Doris; Elf Atochem S.A., DCRD/DPI, Cours Michelet, La Défense 10, F-92091 Paris la Défense Cedex (FR).
- (81) Designated states (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated states (regional): ARIPO Patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). OAPI Patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

With the International Search Report.

For an explanation of the two-letter codes and the other abbreviations, reference is made to the explanations ("Guidance Notes on Codes and Abbreviations") at the beginning of each regular edition of the PCT Gazette.

As printed


(54) Title: AMINOGUANIDINE BICARBONATE WITH PARTICULAR PROPERTIES AND METHOD FOR MAKING SAME

(54) Titre: BICARBONATE D'AMINOGUANIDINE DE PROPRIETES PARTICULIERES ET SON PROCEDE DE FABRICA-TION

(57) Abstract: The invention concerns a method for making aminoguanidine bicarbonate from an aqueous solution of cyanamide and an aqueous solution of hydrazine hydrate in the presence of CO₂. The invention is characterised in that it consists in proceeding with an amount of cyanide slightly higher than the stoichiometric quantity. The invention also concerns quasi-spherical agglomerates of aminoguanidine bicarbonate crystals.


(57) Abrégé: La présente invention concerne un procédé de fabrication de bicarbonate d'aminoguanidine à partir d'une solution) aqueuse de cyanamide et d'une solution aqueuse d'hydrate d'hydrazine en présence de CO₂ caractérisé en ce que l'on opère avec un léger défaut en cyanamide par rapport à la stoechiométrie. Elle a également pour objet des agglomérats quasi sphériques de cristaux de bicarbonate d'aminoguanidine.

1/3




PHOTOGRAPH N° 1/3

2/3



PHOTOGRAPH N° 2/3

3/3



PHOTOGRAPH N° 3/3



As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below at 201 et seq. beneath my name.

I believe I am the original, first and sole inventor if only one name is listed at 201 below, or an original, first and joint inventor if plural names are listed at 201 et seq. below, of the subject matter which is claimed and for which a patent is sought on the invention entitled

AMINOGUANIDINE BICARBONATE WITH PARTICULAR PROPERTIES AND PROCESS FOR MANUFACTURING IT

and for which a patent application:

☐ is attached hereto and includes amendment(s) filed on (if applicable)

was filed in the United States on as Application No. 10/031,113

with amendment(s) filed on January 11, 2002

was filed as PCT international Application No. PCT/FR00/01579 on June 8, 2000 and was amended under PCT Article 19 on (fapplicable)

I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

	EARLIEST FOREIGN APPLICA	TION(S), IF ANY, FILED PRI	OR TO THE FILING DATE	OF THE APPLICATION
	APPLICATION NUMBER	COUNTRY	DATE OF FILING (day, month, year)	PRIORITY CLAIMED
<u> </u>	99/09257	France	July 16, 1999	YES ⊠ NO □
				YES - NO -
				YES D NO D

hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

PROVISIONAL APPLICATION NUMBER		FILING DATE	
-			
<u> </u>			

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information known to me which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

NON-PROVISIONAL APPLICATION SERIAL NO.		STATUS		
	FILING DATE	PATENTED	PENDING	ABANDONED

(1)

NY2 - 1271657.1

^{*} for use only when the application is assigned to a company, partnership or other organization.

15/04/02 20:35

PENNIE & EDMONDS up DOCKET NO. 2988-0695

may jeopardize the validity of the application or any patent issuing thereon. LASTNAME FIRST NAME MIDDLE NAME **FULL NAME** Bossoutrot Jean-Michel OF INVENTOR-STATE OR FOREIGN COUNTRY COUNTRY OF CITIZENSHIP RESIDENCE & Ó France Chaponost France CITIZENSHIP-STREET STATE OR COUNTRY ZIP CODE POST OFFICE F-69630 8 Chemin de Traine-Fesses Chaponost France **ADDRESS** SIGNATURE OF INVENTOR 20) DATE AjaP24, 2002 LAST NAME FIRST NAME MIDDLE NAME **FULL NAME** Bourdauducq Paul OF INVENTOR 2 CITY COUNTRY OF CITIZENSHIP STATE OR FOREIGN COUNTRY RESIDENCE & 0 Chaponost France France CITIZENSHIP STREET STATE OR COUNTRY 21P CODE POST OFFICE 8, rue des Anemones Chaponost France F-69630 **ADDRESS** SIGNATURE OF INVENTOR 202 April 24, 2002 LAST NAME FIRST NAME MIDDLE NAME **FULL NAME** OF INVENTOR 2 CITY STATE OR FOREIGN COUNTRY COUNTRY OF CITIZENSHIP RESIDENCE & 0 CITIZENSHIP STREET CITY STATE OR COUNTRY ZIP CODE POST OFFICE ADDRESS SIGNATURE OF INVENTOR 201 LAST NAME FIRST NAME MIDDLE NAME **FULL NAME** OF INVENTOR CITY STATE OR FOREIGN COUNTRY COUNTRY OF CITIZENSHIP Ó RESIDENCE & CITIZENSHIP STREET STATE OR COUNTRY ZIPCODE POST OFFICE ADDRESS SIGNATURE OF INVENTOR 2014 LAST NAME PIRST NAME MIOULE NAME **FULL NAME** OF INVENTOR 2 CITY STATE OR FOREIGN COUNTRY COUNTRY OF CITIZENSHIP O RESIDENCE & 5 CITIZENSHIP STREET CITY STATE OR COUNTRY POST OFFICE ZIP CODE **ADDRESS** SIGNATURE OF INVENTOR 205 DATE

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements

United States Patent & Trademark Office Office of Initial Patent Examination -- Scanning Division



zhhueamon deneten	cies iouna auring	scanning:	
□ Page(s)	of		were not present
for scanning.		(Document title)	
□ Page(s)	of		were not present
for scanning.		(Document title)	

Scanned copy is best available. Travilly over too doork